Navigation Links
BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout
Date:1/22/2015

MADISON, Wis., Jan. 15, 2015 /PRNewswire/ -- BellBrook Labs, a leader in high throughput screening assays for drug discovery, announced the launch of a TR-FRET (time resolved Forster resonance energy transfer) version of the company's Transcreener UDP Assay, a high throughput screening assay for glycosyltransferases and other UDP-producing enzymes. The new assay will allow for sensitive detection of hundreds of human and microbial enzymes of potential therapeutic interest for cancer, inherited metabolic disorders, infectious diseases, and other diseases. The TR-FRET detection mode is a preferred readout for HTS because it relies on a time-gated luminescence signal, making it resistant to interference from fluorescent compounds in chemical libraries. The new Transcreener UDP TR-FRET Assay will better serve a growing need for robust, HTS-proven glycosyltransferase assays for drug discovery.

Photo - http://photos.prnewswire.com/prnh/20150114/169233-INFO

Glycosylation controls the function and localization of thousands of human proteins and is central in bacterial cell wall synthesis. Selective targeting of glycosyltransferases may offer new avenues for therapeutic intervention in diverse diseases, including cancer, inherited metabolic disorders, and infectious diseases.  BellBrook Labs pioneered the development of HTS-compatible assays for glycosyltransferases with the introduction of the Transcreener UDP Assay in 2005.  Transcreener is the only HTS-compatible glycosyltransferase assay method that relies on direct detection of reaction products and does not depend on coupling enzymes, which are prone to interference.  Designed specifically for HTS and featuring a single addition mix-and-read format and room temperature reagent stability, the Transcreener UDP TR-FRET Assay is compatible with plate readers typically found in research labs as well as those used in HTS core facilities.  These improvements should accelerate efforts to identify glycosyltransferase inhibitors for use as molecular probes and as potential drug scaffolds.

About BellBrook Labs:
BellBrook Labs, LLC develops detection reagents and microfluidic devices that accelerate the discovery of more effective therapies for cancer and other debilitating diseases. Transcreener® is a universal, high throughput biochemical assay platform based on detection of nucleotides, including ADP, GDP, AMP, GMP and UDP which are formed by thousands of cellular enzymes, many of which catalyze the covalent regulatory reactions that are central to cell signaling and represent new opportunities for therapeutic intervention.  The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology. Visit BellBrook's website for more information: www.bellbrooklabs.com

Media Contact:
Robert Lowery
608-227-4501


'/>"/>
SOURCE BellBrook Labs
Copyright©2015 PR Newswire.
All rights reserved

Related biology news :

1. Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain
2. Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner
3. Atmel Launches Industrys First Wide-V(cc) Low-Power Temperature Sensor Family
4. CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation
5. Cross Match Launches New Identity Management Handheld Solution
6. GENiSYSS Launches Website about Easy, Inexpensive Home DNA Storage for Everyone
7. Tute Genomics Launches MyGene Portal for Genome-guided Medicine
8. Vrai Mobile Limited Launches a Consumer Voice Biometric Application for Mobile Devices
9. BGI Tech launches 2 major NGS service options to suit customers specific needs
10. Princeton University launches NSF-funded initiative to study Southern Oceans role in global systems
11. Frontiers launches a new open-access medical journal: Frontiers in Cardiovascular Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2018)... ... September 14, 2018 , ... ... This campaign will showcase the innovative work being done within rare diseases research, ... therapies for those living with rare diseases. , The print ...
(Date:9/12/2018)... ... September 12, 2018 , ... Captiva Spine, Inc., which designs, ... received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ... , TowerLOX-EXT MIS Extended Tab Pedicle Screws provide the narrow insertion of an ...
(Date:9/1/2018)... ... ... Right this minute, Frenchman Ben Lecomte is hard at work on his second ocean crossing. ... a new challenge: going from Tokyo to San Francisco, churning his limbs eight hours a ... boat. As the first expedition of its kind, The Swim is far more than just ...
Breaking Biology News(10 mins):
(Date:9/7/2018)... , ... September 06, 2018 , ... ... compliance and commercialization, is releasing the agenda for its upcoming user conference. ... science industries discussing the latest challenges, opportunities, and approaches to regulatory compliance and ...
(Date:9/7/2018)... (PRWEB) , ... September 06, 2018 , ... Akadeum Life ... has spent his career as an executive and leader of numerous biotech companies. ... cell therapy and biologics company acquired by Thompson Street Capital in St. Louis, MO. ...
(Date:8/31/2018)... ASTORIA, Ore. (PRWEB) , ... August 29, 2018 ... ... holding Associate Professorships at both the University of Southampton and the Institute of ... and artificial intelligence at sea can dramatically accelerate the exploration and study of ...
(Date:8/29/2018)... CARMEL, Ind. (PRWEB) , ... August 28, 2018 ... ... company selling nano-technology enhanced spinal implants, announced today the successful completion of a ... 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital, and Ellipsis Ventures. ...
Breaking Biology Technology: